NCT01854034View on ClinicalTrials.gov

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AUY922

AUY922 administered intravenously once a week at 70mg/m2

Trial Locations (4)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01854034 - Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR | Biotech Hunter | Biotech Hunter